Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).

Nishimura M, Kogawa T, Sugiyama K, Ozaki Y, Tanabe Y, Funasaka C, Kurozumi S, Yoshimura A, Iwasa T, Sakai H, Morita M, Watanabe S, Fujii T, Yamamoto M, Tsuji Y, Terada M, Ota T, Tokunaga S, Shimokawa M, Takano T

Open source

DOI: 10.1007/s10549-026-08031-2
Published: 2026 Jul 20
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-08031-2,
  title = {Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).},
  author = {Nishimura M and Kogawa T and Sugiyama K and Ozaki Y and Tanabe Y and Funasaka C and Kurozumi S and Yoshimura A and Iwasa T and Sakai H and Morita M and Watanabe S and Fujii T and Yamamoto M and Tsuji Y and Terada M and Ota T and Tokunaga S and Shimokawa M and Takano T},
  year = {2026},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-026-08031-2},
  url = {https://doi.org/10.1007/s10549-026-08031-2}
}

RIS

TY  - JOUR
TI  - Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).
AU  - Nishimura M
AU  - Kogawa T
AU  - Sugiyama K
AU  - Ozaki Y
AU  - Tanabe Y
AU  - Funasaka C
AU  - Kurozumi S
AU  - Yoshimura A
AU  - Iwasa T
AU  - Sakai H
AU  - Morita M
AU  - Watanabe S
AU  - Fujii T
AU  - Yamamoto M
AU  - Tsuji Y
AU  - Terada M
AU  - Ota T
AU  - Tokunaga S
AU  - Shimokawa M
AU  - Takano T
PY  - 2026
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-026-08031-2
UR  - https://doi.org/10.1007/s10549-026-08031-2
ER  -

APA

M, N., T, K., K, S., Y, O., Y, T., C, F., S, K., A, Y., T, I., H, S., M, M., S, W., T, F., M, Y., Y, T., M, T., T, O., S, T., M, S., & T, T. (2026). Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-08031-2

Source records

pubmed · retrieved 2026-09-25T10:18:28.427Z